Abstract
VISUAL ABSTRACT CAN BE FOUND HERE
Objectives In the first full year of the COVID-19 pandemic (2020), South Asians living in the Greater Toronto Hamilton and Vancouver Areas experienced specific barriers to accessing SARS-CoV-2 testing and receiving reliable health information. However, between June 2021 and February 2022, the proportion of people having received at least 1 dose of a COVID-19 vaccine was higher among this group (96%) than among individuals who were not visible minorities (93%). A better understanding of successful approaches and the challenges experienced by those who remain unvaccinated among this highly vaccinated group may improve public health outreach in subsequent waves of the current pandemic or for future pandemic planning. Using qualitative methods, we sought to explore the perceptions of COVID-19 risk, vaccine access, uptake, and confidence among South Asians living in Canada.
Methods In this qualitative study, we interviewed 25 participants between July 2021 and January 2022 in the Greater Toronto Hamilton and Greater Vancouver Areas (10 community members, 9 advocacy group leaders, 6 public health staff). We conducted initial and focused coding in duplicate and developed salient themes. Throughout this process, we held frequent discussions with members of the study’s advisory group to guide data collection as it relates to community engagement, recruitment, and data analysis.
Results Access to and confidence in the COVID-19 vaccine was impacted by individual risk perceptions; sources of trusted information (ethnic and non-ethnic); impact of COVID-19 and the pandemic on individuals, families, and society; and experiences with COVID-19 mandates and policies (including temporal and generational differences). Approaches that include community-level awareness and tailored outreach as it relates to language and cultural context were considered successful.
Conclusion Understanding factors and developing strategies that build vaccine confidence can guide our approach to increase vaccine acceptance in the current and future pandemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this research was provided to principal investigator, Dr. Sonia Anand by the following program: Sero-Surveillance and Research (COVID-19 Immunity Task Force Initiative) Grant agreement #: 2122-HQ-000058 and Immunization Partnership Fund: 2122-HQ-000340
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Hamilton Integrated Research Ethics Board # 13323 March 24, 2021) and the British Columbia Research Ethics Board # H2100866 June 18, 2021) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declarations:
Funding: Funding for this research was provided to principal investigator, Dr. Sonia Anand by the following program: Sero-Surveillance and Research (COVID-19 Immunity Task Force Initiative) Grant agreement #: 2122-HQ-000058 and Immunization Partnership Fund: 2122-HQ-000340
Conflict of Interest: None to declare
Ethics Approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Hamilton Integrated Research Ethics Board # 13323 - March 24, 2021) and the British Columbia Research Ethics Board # H21-00866 – June 18, 2021) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
Consent for publication: Not applicable
Availability of data and material: All available data is included in this publication
Code availability: Not applicable
Data Availability
All data produced in the present work are contained in the manuscript.
